Neurology News

Patients with chronic pain receiving long-term opioid therapy who were assigned to cognitive behavioral therapy reported reductions in pain and pain-related disability, data show.

In a recent population-based cohort study, researchers observed an increased risk for cerebral venous sinus thrombosis after administration of the Johnson & Johnson COVID-19 vaccine.

Reyvow, Nurtec ODT and Ubrelvy were less efficacious than triptans for treating migraines, but these new pharmacologic agents correlated with fewer adverse events, according to a study published in JAMA Network Open.

Healio’s most-viewed neurology stories in October highlight cognitive impairment after COVID-19 infection, vaccine risks and advances in Alzheimer’s therapies, including the FDA granting breakthrough therapy designation for gantenerumab.

As we approach year end, many physicians inquire about ways to reduce their tax obligations for the current tax year.

The FDA has classified Zimmer Biomet’s recall of a robotic platform for neurosurgeons as Class 1, the most serious type of recall.

Small fiber neuropathy appears to have an increasing incidence rate, with greater trends toward obesity, according to study results published in Neurology.

Researchers found rare neurological adverse events related to two COVID-19 vaccines, as well as to infection with the virus itself, but concluded the risks are greater among those who were infected, according to a study in Nature Medicine.

High and low free thyroxine levels are associated with lower global brain perfusion in adults and could lead to brain diseases, such as dementia, according to a presenter.